Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound βE/β0-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The βE-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated βE-globin with partial instability. When this is compounded with a non-functional β0 allele, a profound decrease in β-globin synthesis results, and approximately half of βE/β0-thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl−1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-bia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, this response was associated with a relative increase in a dominant myeloid clone bearing a lentiviral vector insertion within the HMGA2 gene locus.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“In the initial study of HSCs transduced with β-globin in patients with β-thalassemia, one patient with βE/β0-thalassemia achieved independence from transfusion [67].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“The relative clonal dominance at the HMGA2 locus that was initially observed in 1 patient in the LG001 study of the HPV569 vector spontaneously subsided while that patient maintained stable HbA T87Q levels.”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
In the citing paper
“The feasibility of the addition of a gene to autologous hematopoietic cells using a lentiviral vector was shown previously in a single patient with β-thalassemia who safely discontinued transfusions for more than 6 years with ongoing, sustained β A-T87Q -globin expression.14,20”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
MicroRNA maturation: stepwise processing and subcellular localization
Lee, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf476 · Cited by 2,478
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“To demonstrate that only one integrated vector provirus was present in cells with the HMGA2 IS, three qPCR experiments were simultaneously performed on the same genomic DNA preparation with primers specific for either (1) a ‘HIV gag packaging signal’ DNA sequence (common to all vector provirus regardless of IS); (2) t…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Lin28 promotes transformation and is associated with advanced human malignancies
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L. A., Lockhart, V. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.392 · Cited by 814
Long-Term Propagation of Distinct Hematopoietic Differentiation Programs In Vivo
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.-J., Brinkman, R., & Eaves, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.015 · Cited by 609
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
Background
Cited by
Items 101–200 of 1,000
Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9
Ben Jehuda, R., Shemer, Y., & Binah, O. (2018) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9811-3 · Cited by 161
Gogol-Döring, A., Ammar, I., Gupta, S., Bunse, M., Miskey, C., Chen, W., Uckert, W., Schulz, T. F., Izsvák, Z., & Ivics, Z. (2016) · Molecular Therapy · doi:10.1038/mt.2016.11 · Cited by 160
Vargas, J. E., Chicaybam, L., Stein, R. T., Tanuri, A., Delgado-Cañedo, A., & Bonamino, M. H. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1047-x · Cited by 154
“The patient was treated with autologous CD34+ cells transduced with a lentiviral vector [65].”
BackgroundInfluentialCappellini, M. D., Porter, J. B., Viprakasit, V., & Taher, A. T. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.001 · Cited by 182
“A successful outcome was also reported after the use of additive globin techniques in one adult patient with severe beta-thalassaemia [107].”
BackgroundSickle Cell Anemia and Its Phenotypes
Williams, T., & Thein, S. L. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021320 · Cited by 201
“F or p er so na l u se o nl y. advanced of these is the antisickling β-globin vector containing the HbAT87Q mutation (Bluebird Bio), which was first tested in a patient with transfusion-dependent HbE/β-thalassemia (41).”
BackgroundHematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Duncan, C. N., Bledsoe, J. R., Grzywacz, B., Beckman, A., Bonner, M., Eichler, F. S., Kühl, J.-S., Harris, M. H., Slauson, S., Colvin, R. A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405541 · Cited by 164
Risks Associated with Lentiviral Vector Exposures and Prevention Strategies
Schlimgen, R., Howard, J., Wooley, D., Thompson, M., Baden, L. R., Yang, O. O., Christiani, D. C., Mostoslavsky, G., Diamond, D. V., Duane, E. G., et al. (2016) · Journal of Occupational & Environmental Medicine · doi:10.1097/jom.0000000000000879 · Cited by 162
“It is unknown at this time if the clone will remain homeostatic or serves as a prelude to oncogenic transformation.(19) Thus, LVVs can cause clonal expansion and may cause oncogenesis through insertional mutagenesis when given purposely in high doses with the intention to modify DNA of human subjects.”
BackgroundShah, N. N., Qin, H., Yates, B., Su, L., Shalabi, H., Raffeld, M., Ahlman, M. A., Stetler-Stevenson, M., Yuan, C., Guo, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000219 · Cited by 165
“Although adverse events associated with insertional mutagenesis have not been reported in gene therapy trials involving lentiviral vectors,(21) vector-mediated clonal expansion has been reported for b-thalassemia gene therapy.(22) Thus, long-term monitoring is mandated by regulatory agencies to assess for this potenti…”
BackgroundMa, N., Liao, B., Zhang, H., Wang, L., Shan, Y., Xue, Y., Huang, K., Chen, S., Zhou, X., Chen, Y., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.496174 · Cited by 158
“Recently, the development of gene therapy based on viral transduction of a normal HBB gene into a patient’s own hematopoietic stem cells raised hopes for those who do not have access to bone marrow transplantation (3, 4).”
BackgroundGammaretroviral Vectors: Biology, Technology and Application
Maetzig, T., Galla, M., Baum, C., & Schambach, A. (2011) · Viruses · doi:10.3390/v3060677 · Cited by 184
“In all cases cellular homeostasis can be impaired, which for example led to deregulation of HMG2A and subsequent clonal dominance in a recent gene therapy trial for beta-thalassemia [182].”
BackgroundBushman, F. D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.009 · Cited by 146
Self-citationGene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β A(T87Q) - Globin Gene
Negre, O., Eggimann, A.-V., Beuzard, Y., Ribeil, J.-A., Bourget, P., Borwornpinyo, S., Hongeng, S., Hacein-Bey, S., Cavazzana, M., Leboulch, P., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.007 · Cited by 159
“1003) became transfusion independent (see details below).(141)”
BackgroundSelf-citationComplications of thalassemia major and their treatment
Borgna-Pignatti, C., & Gamberini, M. R. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.29 · Cited by 161
Zonari, E., Desantis, G., Petrillo, C., Boccalatte, F. E., Lidonnici, M. R., Kajaste-Rudnitski, A., Aiuti, A., Ferrari, G., Naldini, L., & Gentner, B. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.010 · Cited by 152
“…carrying semi-random LV integrations would reduce the integration load 10-fold, thereby decreasing the chances of gain-of-function events due to insertional mutagenesis, which may originate from immortalized progenitor cells (Cavazzana-Calvo et al., 2010; Stein et al., 2010; Braun et al., 2014).”
BackgroundXu, P., Tong, Y., Liu, X.-Z., Wang, T.-T., Cheng, L., Wang, B.-Y., Lv, X., Huang, Y., & Liu, D.-P. (2015) · Scientific Reports · doi:10.1038/srep12065 · Cited by 149
“Gene therapy in which a normal HBB gene is provided to a patient’s own HSCs via viral transduction is a potential treatment for β -thalassemia 11,12 .”
Molecular mechanisms of retroviral integration site selection
Kvaratskhelia, M., Sharma, A., Larue, R. C., Serrao, E., & Engelman, A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku769 · Cited by 135
Tucci, F., Galimberti, S., Naldini, L., Valsecchi, M. G., & Aiuti, A. (2022) · Nature Communications · doi:10.1038/s41467-022-28762-2 · Cited by 145
Gene therapy: progress and predictions
Collins, M. K., & Thrasher, A. J. (2015) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2014.3003 · Cited by 176
α-Globin as a molecular target in the treatment of β-thalassemia
Mettananda, S., Gibbons, R. J., & Higgs, D. R. (2015) · Blood · doi:10.1182/blood-2015-03-633594 · Cited by 132
Lee, Y. T., de Vasconcellos, J. F., Yuan, J., Byrnes, C., Noh, S.-J., Meier, E. R., Kim, K. S., Rabel, A., Kaushal, M., Muljo, S. A., et al. (2013) · Blood · doi:10.1182/blood-2012-12-472308 · Cited by 142
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases
Wilen, C. B., Wang, J., Tilton, J. C., Miller, J. C., Kim, K. A., Rebar, E. J., Sherrill-Mix, S. A., Patro, S. C., Secreto, A. J., Jordan, A. P. O., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002020 · Cited by 142
“In contrast, the safety record of hematopoietic stem cell gene therapy is less clear, with a significant frequency of gene-therapy induced oncogenesis or clonal outgrowth reported in several hematopoietic stem cell trials [56,57].”
BackgroundSelf-citationCurrent Progress in Therapeutic Gene Editing for Monogenic Diseases
Prakash, V., Moore, M., & Yáñez-Muñoz, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.5 · Cited by 138
Marcucci, K. T., Jadlowsky, J. K., Hwang, W.-T., Suhoski-Davis, M., Gonzalez, V. E., Kulikovskaya, I., Gupta, M., Lacey, S. F., Plesa, G., Chew, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.012 · Cited by 136
Kanter, J., Thompson, A. A., Pierciey, F. J., Hsieh, M., Uchida, N., Leboulch, P., Schmidt, M., Bonner, M., Guo, R., Miller, A., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26741 · Cited by 134
Self-citationEstimating abundances of retroviral insertion sites from DNA fragment length data
Berry, C. C., Gillet, N. A., Melamed, A., Gormley, N., Bangham, C. R. M., & Bushman, F. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts004 · Cited by 130
“…leading to intense interest in the relationship of vector integration sites in the human genome to the size of cell populations harboring that clone (Cavazzana-Calvo et al. , 2010; Deichmann et al. , 2007; Gabriel et al. , 2009; Hacein-Bey-Abina et al. , 2008; Wang et al. , 2010, 2007, 2008).”
Self-citationNobles, C. L., Sherrill-Mix, S., Everett, J. K., Reddy, S., Fraietta, J. A., Porter, D. L., Frey, N., Gill, S. I., Grupp, S. A., Maude, S. L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130144 · Cited by 130
Self-citationGene Therapy for β-Hemoglobinopathies
Cavazzana, M., Antoniani, C., & Miccio, A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.024 · Cited by 124
Cesana, D., Sgualdino, J., Rudilosso, L., Merella, S., Naldini, L., & Montini, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62189 · Cited by 127
Mechanisms of Retroviral Integration and Mutagenesis
Cavazza, A., Moiani, A., & Mavilio, F. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.203 · Cited by 125
“Insertion of a lentiviral vector in a proto-oncogene likewise caused clonal expansion in at least one patient undergoing gene therapy for beta-thalassemia (Cavazzana-Calvo et al., 2010).”
InfluentialINSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes
Sherman, E., Nobles, C., Berry, C. C., Six, E., Wu, Y., Dryga, A., Malani, N., Male, F., Reddy, S., Bailey, A., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.11.002 · Cited by 124
Self-citationGene Therapy with the Sleeping Beauty Transposon System
Kebriaei, P., Izsvák, Z., Narayanavari, S. A., Singh, H., & Ivics, Z. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.08.008 · Cited by 140
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
Fleischer, L. C., Spencer, H. T., & Raikar, S. S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0801-y · Cited by 135
Negre, O., Bartholomae, C., Beuzard, Y., Cavazzana, M., Christiansen, L., Courne, C., Deichmann, A., Denaro, M., Dreuzy, E., Finer, M., et al. (2014) · Current Gene Therapy · doi:10.2174/1566523214666141127095336 · Cited by 126
“We previously reported that a patient with -thalassemia major ( / ) became transfusion independent after autologous transplantation with CD34 cells transduced with the LentiGlobin HPV569 lentiviral vector [3].”
BackgroundInfluentialSelf-citationRivella, S. (2015) · Haematologica · doi:10.3324/haematol.2014.114827 · Cited by 123
Optogenetics and Translational Medicine
Chow, B. Y., & Boyden, E. S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3003101 · Cited by 124
Happle, C., Lachmann, N., Škuljec, J., Wetzke, M., Ackermann, M., Brennig, S., Mucci, A., Jirmo, A. C., Groos, S., Mirenska, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009750 · Cited by 122
Human artificial chromosomes for gene delivery and the development of animal models
Kazuki, Y., & Oshimura, M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.136 · Cited by 108
Gutiérrez-Guerrero, A., Cosset, F., & Verhoeyen, E. (2020) · Viruses · doi:10.3390/v12091016 · Cited by 131
“Others, like WAS [9,16,19,81] and X-linked CGD X-CGD [82] were not as successful, showing major complications and revealed the requirement to improve vector systems [76].”
BackgroundGenomic discovery of potent chromatin insulators for human gene therapy
Liu, M., Maurano, M. T., Wang, H., Qi, H., Song, C.-Z., Navas, P. A., Emery, D. W., Stamatoyannopoulos, J. A., & Stamatoyannopoulos, G. (2015) · Nature Biotechnology · doi:10.1038/nbt.3062 · Cited by 121
The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases
Abdelnour, S. A., Xie, L., Hassanin, A. A., Zuo, E., & Lu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.699597 · Cited by 144
Emerging genetic therapy for sickle cell disease
Orkin, S. H., & Bauer, D. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041817-125507 · Cited by 119
Genetically modified mesenchymal stromal cells in cancer therapy
Sage, E. K., Thakrar, R. M., & Janes, S. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.09.003 · Cited by 119
“[68] Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K,”
A network of heterochronic genes including Imp1 regulates temporal changes in stem cell properties
Nishino, J., Kim, S., Zhu, Y., Zhu, H., & Morrison, S. J. (2013) · eLife · doi:10.7554/elife.00924 · Cited by 123
“HMGA2 also promotes hematopoietic stem cell selfrenewal (Cavazzana-Calvo et al., 2010; Ikeda et al., 2011) and myoblast proliferation (Li et al., 2012). let-7 microRNAs are evolutionarily conserved heterochronic genes that regulate developmental timing (Pasquinelli et al., 2000) and aging (Shen et…”
BackgroundGenetic engineering of hematopoiesis: current stage of clinical translation and future perspectives
Naldini, L. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809958 · Cited by 110
Gene therapy for neurological disorders: challenges and recent advancements
Peña, S., Iyengar, R., Eshraghi, R. S., Bencie, N., Mittal, J., Aljohani, A., Mittal, R., & Eshraghi, A. A. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1630415 · Cited by 122
“Gene therapy has successfully treated several inherited immune deficiencies including severe combined immune deficiency (SCID) and adenosine deaminase (ADA) deficiency, hereditary blindness [18,19] blood disorders such as haemophilia [20,21] and beta thalassemia [22,23], amyotrophic lateral sclerosis (ALS), spinal mus…”
BackgroundRecent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15038 · Cited by 114
Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Wu, C., & Dunbar, C. E. (2011) · Frontiers of Medicine · doi:10.1007/s11684-011-0159-1 · Cited by 114
Genetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression
Escobar, G., Moi, D., Ranghetti, A., Ozkal-Baydin, P., Squadrito, M. L., Kajaste-Rudnitski, A., Bondanza, A., Gentner, B., De Palma, M., Mazzieri, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3006353 · Cited by 113
Vranckx, L. S., Demeulemeester, J., Saleh, S., Boll, A., Vansant, G., Schrijvers, R., Weydert, C., Battivelli, E., Verdin, E., Cereseto, A., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.039 · Cited by 113
“Insertional mutagenesis due to deregulation of neighboring gene expression is a concern in gene therapy applications with lentiviral vectors (Cavazzana-Calvo et al., 2010).”
Backgroundβ-globin gene transfer to human bone marrow for sickle cell disease
Romero, Z., Urbinati, F., Geiger, S., Cooper, A. R., Wherley, J., Kaufman, M. L., Hollis, R. P., Ruiz de Assin, R., Senadheera, S., Sahagian, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67930 · Cited by 107
“This anti-sickling construct corrected SCD in 2 murine models of the disease, and a similar LV has been used in a clinical trial for β-thalassemia and SCD in France (31).”
InfluentialIkeda, K., Mason, P. J., & Bessler, M. (2011) · Blood · doi:10.1182/blood-2011-02-334425 · Cited by 112
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana, M., Six, E., Lagresle-Peyrou, C., André-Schmutz, I., & Hacein-Bey-Abina, S. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.137 · Cited by 106
“72 Indeed, the thalassemia patient initially showing a dominant clone in the HMGA2 locus is still free of any complication 8 years after gene therapy 73 (M. Cavazzana and S. Hacein-Bey-Abina, unpublished observations).”
Self-citationDesigning Lentiviral Vectors for Gene Therapy of Genetic Diseases
Poletti, V., & Mavilio, F. (2021) · Viruses · doi:10.3390/v13081526 · Cited by 120
“In at least one case, however, premature transcript termination caused up-regulation rather than down-regulation of a genomic transcript, and a gain-of-function effect: in a patient undergoing gene therapy for β-thalassemia, elimination of a miRNA target sequence in the 3′ UTR of the HMGA2 gene transcripts due to an L…”
BackgroundLong-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial
Magrin, E., Semeraro, M., Hebert, N., Joseph, L., Magnani, A., Chalumeau, A., Gabrion, A., Roudaut, C., Marouene, J., Lefrère, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01650-w · Cited by 119
Self-citationConstruction of stable packaging cell lines for clinical lentiviral vector production
Sanber, K. S., Knight, S. B., Stephen, S. L., Bailey, R., Escors, D., Minshull, J., Santilli, G., Thrasher, A. J., Collins, M. K., & Takeuchi, Y. (2015) · Scientific Reports · doi:10.1038/srep09021 · Cited by 108
Gene therapy for severe combined immunodeficiencies and beyond
Fischer, A., & Hacein‐Bey‐Abina, S. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190607 · Cited by 111
“…vivo CD34 hematopoietic progenitors in different diseases), since the 44 patients with ≥4 yr of follow-up are all leukemia free (Cartier et al., 2009; Cavazzana-Calvo et al., 2010; Aiuti et al., 2013; Biffi et al., 2013; Hacein-Bey-Abina et al., 2014; Ferrua et al., 2019; Sessa et al., 2016;…”
BackgroundSelf-citationRetroviral Integrations in Gene Therapy Trials
Biasco, L., Baricordi, C., & Aiuti, A. (2012) · Molecular Therapy · doi:10.1038/mt.2011.289 · Cited by 106
Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins
Maeda, Y., & Kinoshita, T. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.05.002 · Cited by 118
Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media
Bauler, M., Roberts, J. K., Wu, C.-C., Fan, B., Ferrara, F., Yip, B. H., Diao, S., Kim, Y.-I., Moore, J., Zhou, S., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.011 · Cited by 104
Bobadilla, S., Sunseri, N., & Landau, N. R. (2013) · Gene Therapy · doi:10.1038/gt.2012.61 · Cited by 103
Extended Survival of Glioblastoma Patients After Chemoprotective HSC Gene Therapy
Adair, J. E., Beard, B. C., Trobridge, G. D., Neff, T., Rockhill, J. K., Silbergeld, D. L., Mrugala, M. M., & Kiem, H. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003425 · Cited by 110
Current and future alternative therapies for beta-thalassemia major
Dreuzy, E. D., Bhukhai, K., Leboulch, P., & Payen, E. (2016) · Biomedical Journal · doi:10.1016/j.bj.2015.10.001 · Cited by 115
“In this vector, referred to as LentiGlobin vector HPV569, the b-globin gene is under the control of the LCR and the b-globin promoter, and is surrounded by tandem copies of the cHS4 core element [148].”
BackgroundMethodSelf-citationReady for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
Ernst, M. P. T., Broeders, M., Herrero-Hernandez, P., Oussoren, E., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.022 · Cited by 107
Cystic Fibrosis Gene Therapy in the UK and Elsewhere
Griesenbach, U., Pytel, K. M., & Alton, E. W. F. W. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.027 · Cited by 94
Targeted Therapeutic Strategies for Fetal Hemoglobin Induction
Sankaran, V. G. (2011) · Hematology · doi:10.1182/asheducation-2011.1.459 · Cited by 117
Rare genetic diseases: update on diagnosis, treatment and online resources
Pogue, R. E., Cavalcanti, D. P., Shanker, S., de Andrade, R. V., Aguiar, L. R., Carvalho, J. L., & Costa, F. F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.11.002 · Cited by 115
The Promise and the Hope of Gene Therapy
Papanikolaou, E., & Bosio, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618346 · Cited by 114
“From a regulatory standpoint, the clonal dominance observed during the French β-thalassemia trial (Cavazzana-Calvo et al., 2010) led to a clinical hold of the specific trial as per FDA guidelines for 5 years, until it was clear that the respective clonal dominance did not evolve to any kind of dysplasia or leukemia an…”
BackgroundCell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
Chapin, J. C., & Giardina, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00040-8 · Cited by 108
Zheng, F., Liao, Y.-J., Cai, M.-Y., Liu, T.-H., Chen, S.-P., Wu, P., Wu, L., Bian, X., Guan, X., Zeng, Y.-X., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1004873 · Cited by 106
Lentiviral Vectors: Their Molecular Design, Safety, and Use in Laboratory and Preclinical Research
Dropulić, B. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.058 · Cited by 98
“Although lentiviral vectors have been safely used in human clinical trials (Levine et al. , 2006; Cartier et al. , 2009; Cavazzana-Calvo et al. , 2010), the focus of this review is on their use in laboratory and preclinical research.”
Oggu, G. S., Sasikumar, S., Reddy, N., Ealla, K. K. R., Rao, C. M., & Bokara, K. K. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9760-2 · Cited by 105
“Results suggest that the hemoglobin levels of the patients were maintained in the range of 9–10 g/dl for almost 3 years, without any transfusions [119].”
Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies
Magrin, E., Miccio, A., & Cavazzana, M. (2019) · Blood · doi:10.1182/blood.2019000949 · Cited by 114
Dynamics of HSPC Repopulation in Nonhuman Primates Revealed by a Decade-Long Clonal-Tracking Study
Kim, S., Kim, N., Presson, A. P., Metzger, M. E., Bonifacino, A. C., Sehl, M., Chow, S. A., Crooks, G. M., Dunbar, C. E., An, D. S., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2013.12.012 · Cited by 102
“More recent clinical trials using lentiviral vectors have tracked repopulation without obvious genotoxic effects, revealing long-term repopulation by thousands of gene-engineered cells (Aiuti et al., 2013; Biffi et al., 2013; Cartier et al., 2009;Cavazzana-Calvo et al., 2010).”
BackgroundGoing non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side
Hudecek, M., Izsvák, Z., Johnen, S., Renner, M., Thumann, G., & Ivics, Z. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1304354 · Cited by 92
“…stem cell (HSC)based gene therapy with integrating viral vectors has clearly provided therapeutic benefit in primary immunodeficiencies (including SCID-X1, ADA-SCID), thalassemia and leukodystrophies (Aiuti et al., 2013a; Biffi et al., 2013; Cartier et al., 2009; Cavazzana-Calvo et al., 2010).”
BackgroundAbsence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products
Cornetta, K., Duffy, L., Turtle, C. J., Jensen, M., Forman, S., Binder-Scholl, G., Fry, T., Chew, A., Maloney, D. G., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.008 · Cited by 98
Self-citationManufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies
Wang, X., & Rivière, I. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.81 · Cited by 96
Gene therapy for leukodystrophies
Biffi, A., Aubourg, P., & Cartier, N. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr142 · Cited by 94
Self-citationEmery, D. W. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.233 · Cited by 92
“…strategies such as drug selection (Emery et al. , 2000) or selective expansion (Emery et al. , 2005), or in cases where disease pathology provides a means of selection, such as X-SCID (Hacein-Bey-Abina et al. , 2002) or b -thalassemia (Nishino et al. , 2006; Cavazzana-Calvo et al. , 2010).”
InfluentialA Molecular Revolution in the Treatment of Hemophilia
Butterfield, J. S. S., Hege, K. M., Herzog, R. W., & Kaczmarek, R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.006 · Cited by 94
Zhao, Y., Stepto, H., & Schneider, C. K. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.078 · Cited by 100
“This is because (1) 293T cells have been widely used in LV production and quantitation; (2) it has been recently reported that the commonly known heterogeneity and instability of HEK293 were largely due to a mix (bulk) cell population—in fact, the established single 293T cell clones show a high karyotype stability and…”
BackgroundMethodInfluentialModulation of immune responses in lentiviral vector-mediated gene transfer
Annoni, A., Gregori, S., Naldini, L., & Cantore, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.012 · Cited by 99
Developmental changes in hematopoietic stem cell properties
Copley, M. R., & Eaves, C. J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.98 · Cited by 95
Müller-Kuller, U., Ackermann, M., Kolodziej, S., Brendel, C., Fritsch, J., Lachmann, N., Kunkel, H., Lausen, J., Schambach, A., Moritz, T., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv019 · Cited by 103
Wang, C. X., Sather, B. D., Wang, X., Adair, J., Khan, I., Singh, S., Lang, S., Adams, A., Curinga, G., Kiem, H.-P., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546218 · Cited by 88
Preclinical and clinical advances in transposon-based gene therapy
Tipanee, J., Chai, Y. C., VandenDriessche, T., & Chuah, M. K. (2017) · Bioscience Reports · doi:10.1042/bsr20160614 · Cited by 89
Clonal-level lineage commitment pathways of hematopoietic stem cells in vivo
Lu, R., Czechowicz, A., Seita, J., Jiang, D., & Weissman, I. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801480116 · Cited by 86
“For example, several gene therapy trials were dismayed by the appearance of clonal dominance in the blood cells of treated patients (44, 45).”
BackgroundThalassemia 2016: Modern medicine battles an ancient disease
Rund, D. G. (2015) · American Journal of Hematology · doi:10.1002/ajh.24231 · Cited by 89
INSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions
Berry, C. C., Nobles, C., Six, E., Wu, Y., Malani, N., Sherman, E., Dryga, A., Everett, J. K., Male, F., Bailey, A., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.11.003 · Cited by 85
Self-citationEngineering Gene Therapy: Advances and Barriers
Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100040 · Cited by 81
Cossu, F. (2010) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/1824-7288-36-76 · Cited by 103
“The recent report of a clonal expansion from integration of Lentivirus vector in the DNA-binding protein HMGA2 (high mobility group AT-hook 2) gene in a patient of the gene therapy trial for thalassemia in France [124] imposes however further caution.”
BackgroundPavani, G., Fabiano, A., Laurent, M., Amor, F., Cantelli, E., Chalumeau, A., Maule, G., Tachtsidi, A., Concordet, J., Cereseto, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020001996 · Cited by 104
Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases
Tucci, F., Scaramuzza, S., Aiuti, A., & Mortellaro, A. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.020 · Cited by 89
“Clinical efficacy with transfusion independence in the treated patients was achieved, but there was some initial concern due to the clonal dominance of an LV vector integration in the HGMA2 gene, which turned out to be benign and self-limiting.(89) More recently, two different phase I/II clinical trials (ClinicalTrial…”
BackgroundLi, S., Ling, S., Wang, D., Wang, X., Hao, F., Yin, L., Yuan, Z., Liu, L., Zhang, L., Li, Y., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.04.021 · Cited by 95
Gene therapy of hemoglobinopathies: progress and future challenges
Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz172 · Cited by 86
Self-citationCarbonaro, D. A., Zhang, L., Jin, X., Montiel-Equihua, C., Geiger, S., Carmo, M., Cooper, A., Fairbanks, L., Kaufman, M. L., Sebire, N. J., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.265 · Cited by 78
Self-citationNon-deletional alpha thalassaemia: a review
Kwaifa, I. K., Lai, M. I., & Noor, S. M. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01429-1 · Cited by 95
Breda, L., Casu, C., Gardenghi, S., Bianchi, N., Cartegni, L., Narla, M., Yazdanbakhsh, K., Musso, M., Manwani, D., Little, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032345 · Cited by 83
“Recently, the first clinical trial on a patient with Hb E/b-thalassemia was reported [17].”
BackgroundZinc-finger nuclease-mediated correction of α-thalassemia in iPS cells
Chang, C.-J., & Bouhassira, E. E. (2012) · Blood · doi:10.1182/blood-2012-03-420703 · Cited by 84
Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects
Mansilla-Soto, J., Riviere, I., Boulad, F., & Sadelain, M. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.037 · Cited by 83
“26 Owing to the genomic instability of the b 87/HVP569 vector, 25 bluebird bio removed the duplicated cHS4 sequence that had been inserted into the vector U3 region upon taking over the therapeutic program from Genetix Pharma, thus creating the BB305 vector (Fig.”
Metadata
- Authors
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chrétien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.-J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chrétien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S., & Leboulch, P.
- Affiliations
- Inserm (FR)
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- University of Trieste (IT)
- Hôpital Intercommunal de Créteil (FR)
- Hôpital Tenon (FR)
- Columbia University Irving Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Indiana University Indianapolis (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7313
- Pages
- 318-322
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3355472
- OpenAlex
- W2136274459
- Cited by
- 1,276
- References
- 32
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 46 · 2023: 53 · 2022: 64 · 2021: 75 · 2020: 76 · 2019: 84 · 2018: 79 · 2017: 97 · 2016: 94 · 2015: 99 · 2014: 94 · 2013: 116 · 2012: 106
- FWCI
- 63.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL090921, HL090921)
- National Institute of Allergy and Infectious Diseases (AI52845, R01AI082020, R01AI052845, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- beta-thalassemia, gene therapy, lentiviral vectors, transfusion independence, HMGA2, leukemia risk, hemoglobinopathies, sickle cell disease, hematopoietic stem cells, alternative splicing, hemoglobin
- MeSH terms
- Adolescent, Blood Cells, Blood Transfusion, Bone Marrow Cells, Child, Preschool, Clone Cells, Genetic Vectors, Homeostasis, Humans, Male, Organ Specificity, RNA, Messenger, Time Factors, Genetic Therapy, Transcriptional Activation, Gene Expression, Lentivirus, beta-Thalassemia, HMGA2 Protein, MicroRNAs, beta-Globins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.